



I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Mail Stop 100, Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 29th day of March 2005.

By

Mary C. Zickel
(Signature of person mailing)

(Signature of person mailing)

Mary C. Bickel

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Laura C. Blumberg, *et al.*

Serial No.: 10/616,844

Filed: July 8, 2003

Title: NOVEL PIPERIDINE DERIVATIVES

)
)
)
)
)
)
)
)
)
)

Group Art Unit: Chang, Celia C

Examiner: 1625

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Sir:

Applicants hereby submit to the U.S. Patent and Trademark Office form PTO-FB-A820 to ensure compliance with the continuing duty of candor as set forth in 37 C.F.R. § 1.56. A copy of the US patent cited therein is not submitted herewith pursuant to 37 C.F.R. §1.98(a). The currently cited document has not been previously submitted to the U.S. Patent and Trademark Office. This submission is intended to augment, and not replace, the Information Disclosure Statements filed previously September 30, 2003 and November 18, 2003.


In the judgment of the undersigned, portions of the document cited in form PTO-FB-A820 may be material to the present application, however, the filing of this Information Disclosure

Statement shall not be construed to be an admission that the document cited is, or is considered to be, material with regard to patentability as defined in 37 C.F.R. § 1.56(b). The document has not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative importance of any portion of the document. This statement is not a representation that the listed document has an effective date early enough to be "prior art" within the meaning of 35 U.S.C. § 102 or § 103.

Because this Information Disclosure Statement is being filed after the mailing of a first Office Action on the merits and before the mailing date of any final action under 37 C.F.R. § 1.113, the Commissioner is hereby authorized to charge the sum of \$180.00 to Deposit Account No. 16-1445 pursuant to 37 C.F.R. § 1.97(c) and § 1.17(p). The Commissioner is further authorized to charge any additional fees or credit any overpayment to Account No. 16-1445.

Respectfully submitted,


Date: March 29, 2005



Christopher J. Verni
Attorney for Applicants
Reg. No. 48,322

Customer No. 28523
Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 686-2032

Doc. #: 81286v1



**SUPPLEMENTAL INFORMATION
DISCLOSURE CITATION**

(Use several sheets if necessary)

PAGE 1 OF 1

ATTY. DOCKET NO. PC25035A

SERIAL NO. 10/616,844

APPLICANT Laura C. Blumberg, et al.

FILING DATE July 8, 2003

GROUP 1625

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	US	4	1	7	3	6	2	6	Nov. 6, 1979	Dempski, et al.	A61K	9/22	

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.